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Prognostic nomogram for bladder cancer
with brain metastases: a National Cancer
Database analysis
Zhixian Yao1† , Zhong Zheng1†, Wu Ke1, Renjie Wang1, Xingyu Mu1, Feng Sun1, Xiang Wang1, Shivank Garg2,
Wenyin Shi2*, Yinyan He3* and Zhihong Liu1*

Abstract
Background: This study aimed to establish and validate a nomogram for predicting brain metastasis in patients with
bladder cancer (BCa) and assess various treatment modalities using a primary cohort comprising 234 patients with
clinicopathologically-confirmed BCa from 2004 to 2015 in the National Cancer Database.
Methods: Machine learning method and Cox model were used for nomogram construction. For BCa patients with
brain metastasis, surgery of the primary site, chemotherapy, radiation therapy, palliative care, brain confinement of
metastatic sites, and the Charlson/Deyo Score were predictive features identified for building the nomogram.
Results: For the original 169 patients considered in the model, the areas under the receiver operating characteristic
curve (AUC) were 0.823 (95% CI 0.758–0.889, P < 0.001) and 0.854 (95% CI 0.785–0.924, P < 0.001) for 0.5- and 1-year
overall survival respectively. In the validation cohort, the nomogram displayed similar AUCs of 0.838 (95% CI 0.738–
0.937, P < 0.001) and 0.809 (95% CI 0.680–0.939, P < 0.001), respectively. The high and low risk groups had median
survivals of 1.91 and 5.09 months for the training cohort and 1.68 and 8.05 months for the validation set, respectively
(both P < 0.0001).
Conclusions: Our prognostic nomogram provides a useful tool for overall survival prediction as well as assessing the
risk and optimal treatment for BCa patients with brain metastasis.
Keywords: Bladder cancer, Brain metastasis, Machine learning, Nomogram, Overall survival
Background
As the top ranked malignancy of the urinary system, bladder cancer (BCa) incidence data in the US shows an estimated 79,030 (8th among all sites) new cases and 16,870
(8th among all sites) deaths in 2017 [1]. Unfortunately,
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10–15% of BCa patients already have metastasis at initial diagnosis and 15–30% high-grade BCa will eventually
progress to advanced disease and lead to poor prognosis
[2].
Despite an initial response to chemotherapy, patients
with non-organ-confined disease fail to attain satisfactory survival [3]. Since no optimally effective chemotherapeutic modality has been found, patients with NOC
disease can barely survive for more than 3–6 months [4].
According to a previous population-based study of the
SEER database, only 4.1% (76/1862) BCa patients had
brain metastases in a cohort of 1862 patients with metastatic sites [5]. Given the rarity of brain metastases at
presentation, currently, there is no randomized phase II
or III clinical trials exploring outcomes of this group. The
survival prognosis of this subgroup calls for significant
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melioration when compared to those with cerebral
metastasis from other malignancies [6].
Some reports have claimed that stereotactic radiosurgery and whole-brain irradiation can be a useful alternative approach for patients with brain metastasis in certain
malignancies [7, 8]; however, suitable treatment for BCa
patients with brain metastases remains unclear. A study
conducted in 2002 in Cleveland retrospectively analyzed
16 BCa patients with brain metastases and suggested
more aggressive treatment rather than radiation therapy
alone [9]. However, the cohort was too small to extract
robust clinical traits. In 2010, Fokas et al. found no significant difference in survival after comparing radiotherapy
alone with radiotherapy plus surgery in 62 patients with
brain metastases from BCa [10]. Therefore, reconsideration of current medical strategies is indispensable, since
the role of surgeries of the primary tumor or radiotherapy of brain lesions in the treatment of metastatic BCa is
still obscure.
Although previous studies have identified several
prognostic factors of poor outcome in advanced BCa,
such as the presence of visceral metastasis, anemia, and
C-reactive protein (CRP) [3, 11, 12], it remains unknown
whether they could be applied to the clinical assessment.
Currently, prognostic nomograms are widely applied as
prognostic devices in oncologic medicine. With the ability to incorporate clinical characteristics to generate individual probabilities of clinical events, nomograms can aid
clinical decisions and facilitate our drive towards personalized medicine [13]. The purpose of our study was
to create a nomogram predicting overall survival (OS) of
BCa patients with brain metastasis and evaluate suitable
therapeutic modalities for this cohort.

Materials and methods
Study population

The National Cancer Database (NCDB) was queried for
patients initially diagnosed with histological confirmed
BCa (topographical code C67, International Classification of Diseases for Oncology, 3rd edition) between 2004
and 2015. Patients with brain metastatic disease at the
time of presentation were selected for the analysis.
Baseline medical traits (including age; sex, race; pathological grade; tumor histology, lymph node vascular
invasion, and clinical stage [TNM] of the American Joint
Committee on Cancer; surgical statuses of the primary
and metastatic sites; chemotherapy; radiation therapy;
and palliative care) were derived from medical records
(Table 1). Other inclusion criteria were as follows:
age > 18 years; BCa as the primary cancer diagnosis; brain
metastasis; other distant metastatic sites including bone,
liver, lung, and distant lymph node involvement; active
follow-up; and patients with > 30 days of survival. Patients
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without sufficient information about distant metastatic
sites or survival data were excluded. No detailed data
were available regarding the specific types of chemotherapy or hormonal therapy or palliative care agents. Finally,
we included 234 patients with the above-mentioned criteria. We used a computer-generated random seed to
assign 169 of these patients to the training set, and 65
patients to the internal testing set for subsequent analysis. Work of flow is displayed in Fig. 1.
Compliance with ethical standards

The NCDB is a hospital-based registry of cases treated
at American College of Surgeons Commission on Cancer accredited cancer programs. Extraction of data from
the NCDB did not require extra informed consent. All
the data were downloaded at the Sidney Kimmel Cancer
Center of Thomas Jefferson University.
Statistical analysis

For feature selection, we used the least absolute shrinkage and selection operator (LASSO) method, which is a
machine learning method suitable for the reduction of
high-dimensional data [14]. Eighteen variables were used
to select the most useful predictive features from the primary data set. The LASSO regression model analysis was
performed using the glmnet package of R (R Foundation
for Statistical Computing, Vienna, Austria).
Univariate and multivariate Cox regression analysis
were performed to explore the independent prognostic factors via the survival package of R. The Schoenfeld
residuals method was applied to test the proportional
hazards assumption for the Cox regression model fit.
Each regression coefficient of selected variables was
converted to a 0 to 100 scale proportion according to its
contribution. These points were added across enrolled
variables to generate total points, which were then transformed to predicted probabilities. For clinical use, the
predictive performance of the nomogram was measured
via time-dependent receiver operating characteristic
(ROC) analysis with area under the curve (AUC) values.
Calibration was employed with bootstrapping to decrease
the bias of over-fitting. The x-axis represented the prediction calculated using the nomogram, and the y-axis
the actual risk odds for the individual. The 45-degree
line represented an ideal performance of the nomogram,
in which the predicted outcome perfectly corresponded
with the actual outcome. The model that incorporated
the above independent predictors was developed and
presented as the nomogram. Nomogram and calibration plots were obtained using the rms and nomogramEx
packages of R.
Survival analysis was performed using the Kaplan–
Meier method to probe the correlation between variables
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Table 1 Description of clinical characteristics and their values
Clinical variables

Description

Age

Age of the patient at diagnosis

Sex

The gender of the patient

Values
< 65 years or ≥ 65 years

Male or female

Race

The primary race of the person

White, black or others

Grade

Describes the tumor’s resemblance to normal tissue (coded
according to ICD-O-3)

Well differentiated, poorly differentiated or Unknown

Tumor_Stage

NCDB analytic stage identifies the clinically or pathologically
determined size and/or extension of the primary tumor (cT)
as defined by the American Joint Committee on Cancer
(AJCC)

High (Stage III, IV) or low (Stage I, II)

Lymph_nodes

Identifies the clinically-determined absence or presence of
regional lymph node metastasis and describes the corresponding extent as defined by the American Joint Committee on Cancer (AJCC)

Yes, no or unknown

Histology

Indicate the pathological histology of tumor cells (coded
according to ICD-O-3)

Transitional cell carcinoma, papillary urothelial carcinoma, small
cell carcinoma or others

Lymph_Vas_invasion Indicate the presence or absence of tumor cells in lymphatic
channels (other than lymph nodes) or blood vessels within
the primary tumor as noted microscopically by the pathologist

Yes, no or unknown

Met_Bone

Indicate the presence of distant involvement of bone at the
time of diagnosis

Yes or no

Met_Liver

Indicate the presence of distant involvement of liver at the
time of diagnosis

Yes or no

Met_Lung

Indicate the presence of distant involvement of lung at the
time of diagnosis

Yes or no

Surgery_Primary

Records the surgical procedure and approach performed to
the primary site

Minimal invasive surgery, non-minimal invasive surgery or no
surgery

Chemotherapy

Records of chemotherapy administrated as first course treatment

Yes or no

Radiation_Therapy

Anatomic target volume is directed at tumors lying within the
substance of brain or its meninges

Yes or no

Paliative_Care

Any care provided an effort to palliate or alleviate symptoms

Yes or no

Brain_Confined_Met Indicate the presence of distant involvement of brain only or
brian combined with other organs at the time of diagnosis

Brain confined or non-brain confined

CDCC_Score

Charlson/Deyo Score, a weighted score derived from the
sum of the scores for each of the comorbid conditions
listed in the Charlson Comorbidity Score Mapping Table
(source http://dx.doi.org/10.17632/nn6y58v8vv.1#file-a7273
5e9-15b5-4a10-aef5-deddad2463e8)

0–3

Surgery_Met

Records the surgical removal of distant lymph nodes or other
tissues or organs beyond the primary site

Yes or no

and OS, and the log-rank test was performed to compare survival variance in different groups. Decision curve
analysis were performed to compare with the current
AJCC TNM staging system. All statistical tests and analyses were performed in R software version 3.5.1. Statistical
significance was set at < 0.05.

Results

in accordance with the inclusion criteria were enrolled,
and 169 and 65 patients were randomly divided into the
training and internal validation cohorts, respectively. The
clinicopathologic characteristics and baseline data in the
primary and validation cohorts are provided in Table 2.
The median follow-up time was 3.38 (range: 1.08–61.21)
months.

Clinicopathologic characteristics

Feature selection via LASSO

During the study procedure, 268 consecutive BCa
patients with brain-involvement were identified from
the NCDB. Of these, 234 patients with brain metastasis

LASSO with tenfold cross-validation generated 7 variables out of 18 features: Grade, Surgery_Primary,
Chemotherapy,
Radiation_Therapy,
Paliative_Care,
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Fig. 1 Flowchart of the analysis

Brain_Confined_Met, and CDCC_Score (Fig. 2a, b). The
results of the univariate and multivariate Cox regression of the primary cohort are recorded in Table 3.
Surgery_Primary, Chemotherapy, Radiation_Therapy,
Paliative_Care, Brain_Confined_Met, and CDCC_Score
were chosen for further analysis (apart from Radiation_Therapy, all other variables were independent prognostic factors in the LASSO Cox model; the reason for
including this variable will be explained in “Discussion”)
P values for Schoenfeld residuals method were all > 0.05
which fitted the proportional hazards assumption for the
Cox model (Additional file 1: Fig. S1).
Development and validation of the prognostic nomogram

The prognostic nomogram that integrated all selected
factors for OS in the primary cohort is shown in Fig. 3.
We then derived a formula to calculate the risk score

for odds of death for every patient based on their individual status of the selected variables above. To take one
patient for example (purple track in Fig. 3), basing on the
selected features, the total points adds up to 323 and thus
the corresponding 0.5- and 1-year death probabilities
are 0.647 and 0.9 respectively. The equation of each variable and computational formula is presented in Table 4.
We further stratified those patients with an average or
higher-than-average risk score into the high risk group
and those with lower-than-average risk score into the low
risk group (Table 1). In terms of 0.5- and 1-year OS of
the training set, our six-clinical variable-based classifier
demonstrated favorable discrimination with AUC values of 0.823 (95% confidence interval [CI] 0.758–0.889,
P < 0.001) and 0.854 (95% CI 0.785–0.924, P < 0.001),
respectively (Fig. 4a). The internal-bootstrapped calibration plot for the probability of survival at 0.5 or 1 year
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Table 2 Baseline characteristics and distribution of risk stratification of patients in the training and validation cohorts
Characteristics

Training set (%)
Number of cases

Internal testing set (%)
High risk

Low risk

Number of cases

High risk

Low risk

Age
< 65 years

71 (42)

32 (18.9)

39 (23.1)

22 (33.8)

11 (16.9)

11 (16.9)

≥ 65 years

98 (58)

49 (29)

49 (29)

43 (66.2)

21 (32.3)

22 (33.8)
28 (43.1)

Sex

Male

128 (75.7)

63 (37.3)

65 (38.5)

47 (72.3)

19 (29.2)

41 (24.3)

18 (10.7)

23 (13.6)

18 (27.7)

13 (20)

White

148 (87.6)

70 (41.4)

78 (46.2)

59 (90.8)

29 (44.6)

Black

16 (9.5)

8 (4.7)

8 (4.7)

4 (6.2)

3 (4.6)

1 (1.5)

5 (3)

3 (1.8)

2 (1.2)

2 (3.1)

0 (0)

2 (3.1)

Female

5 (7.7)

Race

Others

30 (46.2)

Grade
Well differentiated

14 (8.3)

10 (5.9)

4 (2.4)

Poorly differentiated

96 (56.8)

39 (23.1)

57 (33.7)

39 (60)

1 (1.5)

19 (29.2)

0 (0)

20 (30.8)

1 (1.5)

Unknown

59 (34.9)

32 (18.9)

27 (16)

25 (38.5)

13 (20)

12 (18.5)
21 (32.3)

Histology
TCC

94 (55.6)

49 (29)

45 (26.6)

38 (58.5)

17 (26.2)

PUC

42 (24.9)

15 (8.9)

27 (16)

8 (12.3)

5 (7.7)

3 (4.6)

SCC

10 (5.9)

3 (1.8)

7 (4.1)

7 (10.8)

2 (3.1)

5 (7.7)

Others

23 (13.6)

14 (8.3)

9 (5.3)

12 (18.5)

8 (12.3)

4 (6.2)

Tumor_Stage
Low

13 (7.7)

7 (4.1)

6 (3.6)

4 (6.2)

2 (3.1)

2 (3.1)

High

156 (92.3)

74 (43.8)

82 (48.5)

61 (93.8)

30 (46.2)

31 (47.7)

Lymph_nodes
No

87 (51.5)

39 (23.1)

48 (28.4)

33 (50.8)

16 (24.6)

17 (26.2)

Yes

36 (21.3)

14 (8.3)

22 (13)

17 (26.2)

9 (13.8)

8 (12.3)

Unknown

46 (27.2)

28 (16.6)

18 (10.7)

15 (23.1)

7 (10.8)

8 (12.3)

No

31 (18.3)

12 (7.1)

19 (11.2)

12 (18.5)

5 (7.7)

7 (10.8)

Yes

29 (17.2)

13 (7.7)

16 (9.5)

6 (9.2)

3 (4.6)

3 (4.6)

109 (64.5)

56 (33.1)

53 (31.4)

47 (72.3)

24 (36.9)

23 (35.4)

Lymph_Vas_Invasion

Unknown
Met_Bone
No

112 (66.3)

47 (27.8)

65 (38.5)

44 (67.7)

26 (40)

18 (27.7)

Yes

57 (33.7)

34 (20.1)

23 (13.6)

21 (32.3)

6 (9.2)

15 (23.1)

Met_Liver
No

129 (76.3)

61 (36.1)

68 (40.2)

50 (76.9)

25 (38.5)

25 (38.5)

Yes

40 (23.7)

20 (11.8)

20 (11.8)

15 (23.1)

7 (10.8)

8 (12.3)

Met_Lung
No

100 (59.2)

40 (23.7)

60 (35.5)

34 (52.3)

16 (24.6)

18 (27.7)

Yes

69 (40.8)

41 (24.3)

28 (16.6)

31 (47.7)

16 (24.6)

15 (23.1)

Surgery_Primary
Minimal invasive

65 (38.5)

27 (16)

38 (22.5)

31 (47.7)

19 (29.2)

12 (18.5)

No

83 (49.1)

48 (28.4)

35 (20.7)

29 (44.6)

9 (13.8)

20 (30.8)

Non-minimal invasive

21 (12.4)

6 (3.6)

15 (8.9)

5 (7.7)

4 (6.2)

1 (1.5)

No

97 (57.4)

77 (45.6)

20 (11.8)

36 (55.4)

28 (43.1)

8 (12.3)

Yes

72 (42.6)

4 (2.4)

68 (40.2)

29 (44.6)

4 (6.2)

25 (38.5)

89 (52.7)

50 (29.6)

39 (23.1)

38 (58.5)

14 (21.5)

24 (36.9)

Chemotherapy

Radiation_Therapy
No
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Table 2 (continued)
Characteristics

Training set (%)

Internal testing set (%)

Number of cases
Yes

80 (47.3)

High risk

Low risk

Number of cases

High risk

Low risk

31 (18.3)

49 (29)

27 (41.5)

18 (27.7)

9 (13.8)

Palliative_Care
No

122 (72.2)

62 (36.7)

60 (35.5)

47 (72.3)

21 (32.3)

Yes

47 (27.8)

19 (11.2)

28 (16.6)

18 (27.7)

11 (16.9)

26 (40)
7 (10.8)

Brain_Confined_Met
No

67 (39.6)

24 (14.2)

43 (25.4)

22 (33.8)

13 (20)

Yes

102 (60.4)

57 (33.7)

45 (26.6)

43 (66.2)

19 (29.2)

24 (36.9)

9 (13.8)

23 (35.4)

CDCC_Score
0

116 (68.6)

50 (29.6)

66 (39.1)

46 (70.8)

23 (35.4)

1

37 (21.9)

19 (11.2)

18 (10.7)

12 (18.5)

8 (12.3)

4 (6.2)

2

10 (5.9)

7 (4.1)

3 (1.8)

5 (7.7)

1 (1.5)

4 (6.2)

3

6 (3.6)

5 (3)

1 (0.6)

2 (3.1)

0 (0)

2 (3.1)

Surgery_Met
No

144 (85.2)

72 (42.6)

72 (42.6)

55 (84.6)

25 (38.5)

30 (46.2)

Yes

25 (14.8)

9 (5.3)

16 (9.5)

10 (15.4)

7 (10.8)

3 (4.6)

TCCtransitional cell carcinoma, PUC papillary urothelial carcinoma, SCC small cell carcinoma

18

17

17

15

15

14

11 7

7

5

5

2

1

1

0

b

10.4

18

18
0.5

a

17

15

11

5

4

3

5

1

16

11
7
5
3

15
9
14

0.5

Coefficients

0.0

10.3
10.2

6
4
10
2
8
18
1

12

10.0

1.0

10.1

Partial Likelihood Deviance

17

13

5

4

3

2

1

6

2

1

log(Lambda)
Log Lambda
Fig. 2 Clinical trait selection via the least absolute shrinkage and selection operator (LASSO) cox regression model. a Tenfold cross-validated error
(first vertical line equals the minimum error (lambda = 0.066), whereas the second vertical line shows the cross-validated error within 1 standard
error of the minimum). b The profile of coefficients in the model at varying levels of penalization plotted against the log (lambda) sequence

after surgery showed an optimal agreement between prediction by nomogram and actual observation (Fig. 4b, c).
In the validation cohort, the nomogram displayed similar
AUC values of 0.838 (95% CI 0.738–0.937, P < 0.001) and
0.809 (95% CI 0.680–0.939, P < 0.001) for the estimation
of survival (Fig. 4d). There was also a well-behaved calibration curve for the survival estimation (Fig. 4e, f ).

Kaplan–Meier survival analysis yielded a significant
difference in survival between the training cohort and
validation set. The median survival of the High and Low
risk groups were 1.91 and 5.09 months in the training
cohort (Fig. 5a) and 1.68 and 8.05 months in the validation set (Fig. 5b), respectively (both P < 0.0001).
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Table 3 Univariate and multivariate Cox regression analysis of BCa patients based on clinicopathological characteristics
derived from NCDB data in the training cohort
Characteristics
Age (< 65 years vs. ≥ 65 years)

Sex (male vs. female)

Univariate analysis HR
(95% CI)

P value

Multivariate analysis HR P value
(95% CI)

1.117 (0.819–1.525)

0.48

1.032 (0.705–1.511)

0.87

0.861 (0.602–1.233)

0.42

1.166 (0.756–1.797)

0.49

Race
White vs. black

0.871 (0.509–1.489)

0.61

0.956 (0.523–1.747)

0.88

White vs. others

0.889 (0.363–2.174)

0.80

0.524 (0.197–1.39)

0.19

Grade
Well differentiated vs. poorly differentiated

0.896 (0.511–1.574)

0.70

1.317 (0.653–2.656)

0.44

Well differentiated vs. unknown

1.144 (0.636–2.057)

0.65

1.634 (0.753–3.546)

0.21

Histology
TCC vs. PUC

0.851 (0.588–1.232)

0.39

1.181 (0.738–1.89)

0.49

TCC vs. SCC

1.083 (0.563–2.087)

0.81

1.495 (0.714–3.13)

0.29

TCC vs. others

0.916 (0.578–1.45)

0.71

0.629 (0.363–1.09)

0.10

Lymph_nodes
No vs. yes

0.835 (0.564–1.234)

0.37

0.808 (0.51–1.28)

0.36

No vs. unknown

0.985 (0.682–1.422)

0.93

0.761 (0.485–1.196)

0.24

Lymph_Vas_Invasion
No vs. yes

1.098 (0.658–1.832)

0.72

1.494 (0.816–2.736)

0.19

No vs. unknown

1.291 (0.859–1.94)

0.22

1.269 (0.764–2.107)

0.36

Tumor_Stage (low vs. high)

1.247 (0.704–2.21)

0.45

1.089 (0.536–2.211)

0.81

Met_Bone (no vs. yes)

1.026 (0.742–1.42)

0.88

0.61 (0.374–0.997)

0.05

Met_Liver (no vs. yes)

0.978 (0.683–1.4)

0.90

1.223 (0.761–1.966)

0.41

Met_Lung (no vs. yes)

1.317 (0.962–1.802)

0.09

0.878 (0.525–1.469)

0.62
< 0.001

Surgery primary
Minimal invasive surgery vs. no surgery

1.44 (1.031–2.011)

0.03

2.529 (1.609–3.975)

0.923 (0.558–1.525)

0.75

1.253 (0.672–2.334)

0.48

Chemotherapy (no vs. yes)

0.353 (0.25–0.498)

< 0.001

0.213 (0.137–0.332)

< 0.001

Radiation_Therapy (no vs. yes)

0.723 (0.53–0.986)

0.04

0.708 (0.486–1.031)

0.07

Minimal invasive surgery vs. non-minimal invasive

Palliative_Care (no vs. yes)

0.922 (0.651–1.305)

0.65

0.631 (0.413–0.964)

0.03

Brain_Confined_Met (non–brain confined vs. brain confined)

1.248 (0.911–1.71)

0.17

2.229 (1.144–4.345)

0.02

CDCC_Score
0 vs. 1

1.29 (0.886–1.878)

0.18

1.439 (0.929–2.23)

0.10

0 vs. 2

1.529 (0.798–2.926)

0.20

1.865 (0.861–4.038)

0.11

0 vs. 3

2.14 (0.932–4.91)

0.07

2.545 (1.035–6.256)

0.04

0.9 (0.58–1.396)

0.64

0.918 (0.546–1.542)

0.75

Surgery_Met (yes vs. no)

Moreover, the decision curve analysis demonstrated
that when the threshold probability was greater than 0.4,
the nomogram presented more net benefit than TNM
system in terms of OS prediction (Fig. 6).

Discussion
In this study, we developed and validated a novel prognostic tool based on six clinical variables to improve the
prediction of OS for patients with confirmed BCa with
metastatic brain lesions. Our results showed that this
tool can well categorize patients into high-risk and lowrisk groups with large differences in OS.

Generally, in our research, prognostic factors are
closely related to the choices of treatment modalities,
as well as the comorbidities and metastatic conditions
of the patient. Known as the best method of determining comorbidity conditions, higher Charlson/Deyo Score
(CDCC_Score) is reported as a poor prognostic factor for
overall mortality and cancer-specific mortality in metastatic BCa [15], consistent with our findings. In a previous study, multisite metastasis was found to be able to
independently predict worse OS compared with single
metastatic sites in BCa patients [5]. Our results are in line
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Fig. 3 Nomogram to estimate the risk and predict the survival of BCa patients with brain metastasis. Bars in blue display the distribution of patients
in the training cohort. To calculate the total points of a specific patient, locate the value of each variable on the top point axis, add the points from
all of the variables, and draw a vertical line from the total point axis to determine the 0.5 and 1 year death probabilities at the lower line of the
nomogram. Purple track provided an example for the calculation of total-points-to-outcome (*P < 0.05, **P < 0.01, ***P < 0.001)

Table 4 The risk point of each variable and computational
formula of OS
Clinical variables

Values

Radiation_Therapy

No

56

Yes

42

No

56

Yes

40

Non-brain confined

73

Brain confined

56

1

56

2

74

Palliative_Care
Brain_Confined_Met
CDCC_Score

Surgery_Primary

Chemotherapy

Risk points

3

76

4

100

No

90

Minimal invasive

56

Non-minimal invasive

53

No

56

Yes

0

0.5-Year Survival = 7.5e−08 * points ^3 − 2.7837e−05 * points
^2 − 0.001082565 * points + 0.815518912
1-Year survival = 1.21e−07 * points ^3 − 2.3544e−05 * points
^2 − 0.003130703 * points + 0.651899934

with the study above since brain-confined metastatic disease was related with better survival.
Treatment for the metastatic group is not beyond dispute. Our study included 4 treatment variables: Surgery_
Primary, Surgery_Met, Chemotherapy, Paliative_Care
and Radiation_Therapy.
A previous study indicated that surgical management
of the primary BCa might contribute to long-term disease-free survival in selected patients [16]. Chen et al.
also suggested that surgical management of the primary
BCa might improve OS outcomes among patients [17].
Our study uncovered that brain metastatic BCa patients
can still benefit from surgical operation of the primary
site via minimal invasive surgery or otherwise. As for
surgeries of the metastatic site, limited conclusions could
be drawn for the lack of unanimous reporting elements
and resection of solitary lung metastasis may result in OS
improvement when integrated with chemotherapy [18].
As shown in the nomogram, though resistance may easily
show up, chemotherapy still exerts maximal survival benefit for brain-metastatic BCa patients, which correlates
to the first-line treatment of the European Association
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Fig. 4 Time-dependent ROC curves comparing the prognostic accuracy of nomogram in BCa patients with metastatic brain lesions in the training
cohort (a) and validation set (d). Validity of the predictive performance of the nomogram in the training cohort (b, c) and validation set (e, f).
Nomogram-predicted probability of overall survival is plotted on the x-axis; actual overall survival is plotted on the y-axis. ROC receiver operator
characteristic, AUC area under the curve

of Urology guidelines [19]. Given that more than half of
patients with metastatic urothelial cancer are unfit for
cisplatin-based chemotherapy, the choice of chemotherapy combination will have to depend on the health condition of patients. Consensus from an international survey
among urologic experts was reached to define patients
unfit for cisplatin-based chemotherapy, which was as
follows: performance score > 1, glomerular filtration
rate ≤ 60 ml/min/1.73 m2, grade 2 audiometric loss and
peripheral neuropathy, and New York Heart Association
class III heart failure [20, 21]. Palliative care is defined
as any procedures to alleviate symptoms distinguishable
from the same modality used for curative intent, which
may include surgery, radiation therapy, systemic therapy,
and/or other pain management drugs. Advanced BCa
can be associated with problems like ureteral obstruction, persistent bleeding, pain, and/or voiding complaints; palliative care may prolong life expectancy in
these patients [22]. The variable Radiation_Therapy was
fitted into the analysis because although the P value 0.07

slightly surpassed 0.05 in the multivariate Cox model, it
was 0.04 in the univariate analysis. Moreover, for brain
metastatic cancer, conventional fractionated whole brain
radiotherapy is still frequently used as a standard therapy
[23]; thus, we included it in the prognostic nomogram for
clinical consideration.
To the best of our knowledge, this is the largest cohort
study exploring the prognostic significance of BCa with
brain metastasis and the effect of various treatments on
patients’ prognoses; however, several limitations are still
noteworthy. For example, information regarding metastasectomy for specific metastatic sites was incomplete. In
addition, there was a lack of details and sequences concerning chemotherapy, endocrine therapy, immunological treatment, and radiation therapy. As a retrospective
study population from different medical facilities, some
baseline characteristics may be non-uniform and external
validation cohorts are needed to confirm the predictive
accuracy of the nomogram.
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Fig. 5 Kaplan–Meier survival analysis for all patients according to our classifier stratified by clinicopathological risk factors. Survival curves show the
overall survival of high risk (blue) and low risk (green) groups between the training cohort (a) and validation set (b). Confidence interval band and
risk table are also added
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Conclusion
By combining six clinical factors of brain-metastatic BCa
patients, we constructed a prognostic nomogram. The
model provides an optimal estimation of OS and reference for suitable treatments in BCa patients with brain
metastasis.
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